FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.